{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T03:46:07Z","timestamp":1793418367505,"version":"4.5.0"},"reference-count":91,"publisher":"American Association for Cancer Research (AACR)","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":119,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020487","name":"Break Through Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020487","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA276268"],"award-info":[{"award-number":["R01 CA276268"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01 CA274276"],"award-info":[{"award-number":["U01 CA274276"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA127003"],"award-info":[{"award-number":["P50CA127003"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA221707"],"award-info":[{"award-number":["P50CA221707"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA218230"],"award-info":[{"award-number":["R01CA218230"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020791","name":"Hale Family Center for Pancreatic Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020791","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005979","name":"Lustgarten Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005979","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001784","name":"Pancreatic Cancer Action Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001784","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>KRAS inhibitors demonstrate clinical efficacy in pancreatic ductal adenocarcinoma (PDAC); however, resistance is common. Among patients with KRASG12C-mutant PDAC treated with adagrasib or sotorasib, mutations in PIK3CA and KRAS, and amplifications of KRASG12C, MYC, MET, EGFR, and CDK6 emerged at acquired resistance. In PDAC cell lines and organoid models treated with the KRASG12D inhibitor MRTX1133, epithelial-to-mesenchymal transition and PI3K-AKT-mTOR signaling associate with resistance to therapy. MRTX1133 treatment of the KrasLSL-G12D\/+; Trp53LSL-R172H\/+; p48-Cre (KPC) mouse model yielded deep tumor regressions, but drug resistance ultimately emerged, accompanied by amplifications of Kras, Yap1, Myc, Cdk6, and Abcb1a\/b, and co-evolution of drug-resistant transcriptional programs. Moreover, in KPC and PDX models, mesenchymal and basal-like cell states displayed increased response to KRAS inhibition compared to the classical state. Combination treatment with KRASG12D inhibition and chemotherapy significantly improved tumor control in PDAC mouse models. Collectively, these data elucidate co-evolving resistance mechanisms to KRAS inhibition and support multiple combination therapy strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Acquired resistance may limit the impact of KRAS inhibition in patients with PDAC. Using clinical samples and multiple preclinical models, we define heterogeneous genetic and non-genetic mechanisms of resistance to KRAS inhibition that may guide combination therapy approaches to improve the efficacy and durability of these promising therapies for patients.<\/jats:p>\n                    <jats:p>See related commentary by Marasco and Misale, p. 2018<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2159-8290.cd-24-0177","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T10:02:00Z","timestamp":1720432920000},"page":"2135-2161","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":308,"title":["Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer"],"prefix":"10.1158","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4006-5285","authenticated-orcid":false,"given":"Julien","family":"Dilly","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2The Broad Institute of Harvard and MIT, Cambridge, Massachusetts."},{"name":"3Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0907-9977","authenticated-orcid":false,"given":"Megan T.","family":"Hoffman","sequence":"additional","affiliation":[{"name":"3Harvard Medical School, Boston, Massachusetts."},{"name":"4Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-9736","authenticated-orcid":false,"given":"Laleh","family":"Abbassi","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2The Broad Institute of Harvard and MIT, Cambridge, Massachusetts."},{"name":"3Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7065-9546","authenticated-orcid":false,"given":"Ziyue","family":"Li","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2The Broad Institute of Harvard and MIT, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6926-1119","authenticated-orcid":false,"given":"Francesca","family":"Paradiso","sequence":"additional","affiliation":[{"name":"5Department of Translational Molecular Pathology, Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8258-1755","authenticated-orcid":false,"given":"Brendan D.","family":"Parent","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2The Broad Institute of Harvard and MIT, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5579-1220","authenticated-orcid":false,"given":"Connor J.","family":"Hennessey","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2The Broad Institute of Harvard and MIT, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3006-7033","authenticated-orcid":false,"given":"Alexander C.","family":"Jordan","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2The Broad Institute of Harvard and MIT, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0390-5812","authenticated-orcid":false,"given":"Micaela","family":"Morgado","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1804-5015","authenticated-orcid":false,"given":"Shatavisha","family":"Dasgupta","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1523-6916","authenticated-orcid":false,"given":"Giselle A.","family":"Uribe","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2The Broad Institute of Harvard and MIT, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4676-6717","authenticated-orcid":false,"given":"Annan","family":"Yang","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2The Broad Institute of Harvard and MIT, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2306-2373","authenticated-orcid":false,"given":"Kevin S.","family":"Kapner","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2The Broad Institute of Harvard and MIT, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7759-5071","authenticated-orcid":false,"given":"Felix P.","family":"Hambitzer","sequence":"additional","affiliation":[{"name":"4Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2354-177X","authenticated-orcid":false,"given":"Li","family":"Qiang","sequence":"additional","affiliation":[{"name":"3Harvard Medical School, Boston, Massachusetts."},{"name":"4Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2133-5374","authenticated-orcid":false,"given":"Hanrong","family":"Feng","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5786-9771","authenticated-orcid":false,"given":"Jacob","family":"Geisberg","sequence":"additional","affiliation":[{"name":"6Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5559-9343","authenticated-orcid":false,"given":"Junning","family":"Wang","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6246-9520","authenticated-orcid":false,"given":"Kyle E.","family":"Evans","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2The Broad Institute of Harvard and MIT, Cambridge, Massachusetts."},{"name":"3Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1093-9364","authenticated-orcid":false,"given":"Hengyu","family":"Lyu","sequence":"additional","affiliation":[{"name":"7Therapeutics Discovery Division, TRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4020-1822","authenticated-orcid":false,"given":"Aislyn","family":"Schalck","sequence":"additional","affiliation":[{"name":"7Therapeutics Discovery Division, TRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1917-9648","authenticated-orcid":false,"given":"Ningping","family":"Feng","sequence":"additional","affiliation":[{"name":"7Therapeutics Discovery Division, TRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7264-2859","authenticated-orcid":false,"given":"Anastasia M.","family":"Lopez","sequence":"additional","affiliation":[{"name":"7Therapeutics Discovery Division, TRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9266-6849","authenticated-orcid":false,"given":"Christopher A.","family":"Bristow","sequence":"additional","affiliation":[{"name":"7Therapeutics Discovery Division, TRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8269-854X","authenticated-orcid":false,"given":"Michael P.","family":"Kim","sequence":"additional","affiliation":[{"name":"7Therapeutics Discovery Division, TRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0472-858X","authenticated-orcid":false,"given":"Kimal I.","family":"Rajapakshe","sequence":"additional","affiliation":[{"name":"5Department of Translational Molecular Pathology, Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7964-6087","authenticated-orcid":false,"given":"Vahid","family":"Bahrambeigi","sequence":"additional","affiliation":[{"name":"5Department of Translational Molecular Pathology, Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5117-5586","authenticated-orcid":false,"given":"Jennifer A.","family":"Roth","sequence":"additional","affiliation":[{"name":"2The Broad Institute of Harvard and MIT, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7361-4699","authenticated-orcid":false,"given":"Kavita","family":"Garg","sequence":"additional","affiliation":[{"name":"8Exact Sciences, Redwood City, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7345-1246","authenticated-orcid":false,"given":"Paola A.","family":"Guerrero","sequence":"additional","affiliation":[{"name":"5Department of Translational Molecular Pathology, Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0410-4037","authenticated-orcid":false,"given":"Ben Z.","family":"Stanger","sequence":"additional","affiliation":[{"name":"9Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1276-186X","authenticated-orcid":false,"given":"Simona","family":"Cristea","sequence":"additional","affiliation":[{"name":"2The Broad Institute of Harvard and MIT, Cambridge, Massachusetts."},{"name":"6Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"10Harvard School of Public Health, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5284-9650","authenticated-orcid":false,"given":"Scott W.","family":"Lowe","sequence":"additional","affiliation":[{"name":"11Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2632-0586","authenticated-orcid":false,"given":"Timour","family":"Baslan","sequence":"additional","affiliation":[{"name":"9Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0201-4444","authenticated-orcid":false,"given":"Eliezer M.","family":"Van Allen","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0692-3717","authenticated-orcid":false,"given":"Joseph D.","family":"Mancias","sequence":"additional","affiliation":[{"name":"3Harvard Medical School, Boston, Massachusetts."},{"name":"12Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7042-7217","authenticated-orcid":false,"given":"Emily","family":"Chan","sequence":"additional","affiliation":[{"name":"13Amgen Inc., Thousand Oaks, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1624-622X","authenticated-orcid":false,"given":"Abraham","family":"Anderson","sequence":"additional","affiliation":[{"name":"13Amgen Inc., Thousand Oaks, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5647-4782","authenticated-orcid":false,"given":"Yuliya V.","family":"Katlinskaya","sequence":"additional","affiliation":[{"name":"13Amgen Inc., Thousand Oaks, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5670-8778","authenticated-orcid":false,"given":"Alex K.","family":"Shalek","sequence":"additional","affiliation":[{"name":"2The Broad Institute of Harvard and MIT, Cambridge, Massachusetts."},{"name":"14Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts."},{"name":"15Institute for Medical Engineering and Science, Department of Chemistry, and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8721-1609","authenticated-orcid":false,"given":"David S.","family":"Hong","sequence":"additional","affiliation":[{"name":"16University of Texas M.D. Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9281-480X","authenticated-orcid":false,"given":"Shubham","family":"Pant","sequence":"additional","affiliation":[{"name":"16University of Texas M.D. Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8443-7116","authenticated-orcid":false,"given":"Jill","family":"Hallin","sequence":"additional","affiliation":[{"name":"17Mirati Therapeutics Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4515-2011","authenticated-orcid":false,"given":"Kenna","family":"Anderes","sequence":"additional","affiliation":[{"name":"17Mirati Therapeutics Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5164-8102","authenticated-orcid":false,"given":"Peter","family":"Olson","sequence":"additional","affiliation":[{"name":"17Mirati Therapeutics Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3166-8922","authenticated-orcid":false,"given":"Timothy P.","family":"Heffernan","sequence":"additional","affiliation":[{"name":"7Therapeutics Discovery Division, TRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1486-0725","authenticated-orcid":false,"given":"Seema","family":"Chugh","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2The Broad Institute of Harvard and MIT, Cambridge, Massachusetts."},{"name":"3Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1835-0335","authenticated-orcid":false,"given":"James G.","family":"Christensen","sequence":"additional","affiliation":[{"name":"17Mirati Therapeutics Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7923-9978","authenticated-orcid":false,"given":"Anirban","family":"Maitra","sequence":"additional","affiliation":[{"name":"5Department of Translational Molecular Pathology, Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0455-1032","authenticated-orcid":false,"given":"Brian M.","family":"Wolpin","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"3Harvard Medical School, Boston, Massachusetts."},{"name":"18Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5374-9918","authenticated-orcid":false,"given":"Srivatsan","family":"Raghavan","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2The Broad Institute of Harvard and MIT, Cambridge, Massachusetts."},{"name":"3Harvard Medical School, Boston, Massachusetts."},{"name":"18Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0943-7407","authenticated-orcid":false,"given":"Jonathan A.","family":"Nowak","sequence":"additional","affiliation":[{"name":"18Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts."},{"name":"19Department of Pathology, Brigham and Women\u2019s Hospital, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6557-3219","authenticated-orcid":false,"given":"Peter S.","family":"Winter","sequence":"additional","affiliation":[{"name":"2The Broad Institute of Harvard and MIT, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2263-363X","authenticated-orcid":false,"given":"Stephanie K.","family":"Dougan","sequence":"additional","affiliation":[{"name":"3Harvard Medical School, Boston, Massachusetts."},{"name":"4Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0701-6203","authenticated-orcid":false,"given":"Andrew J.","family":"Aguirre","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2The Broad Institute of Harvard and MIT, Cambridge, Massachusetts."},{"name":"3Harvard Medical School, Boston, Massachusetts."},{"name":"18Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,7,5]]},"reference":[{"key":"2026041310003610500_bib1","first-page":"7","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2026041310003610500_bib2","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1056\/NEJMra0901557","article-title":"Pancreatic cancer","volume":"362","author":"Hidalgo","year":"2010","journal-title":"N Engl J Med"},{"key":"2026041310003610500_bib3","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1126\/science.aam7622","article-title":"Drugging RAS: know the enemy","volume":"355","author":"Papke","year":"2017","journal-title":"Science"},{"key":"2026041310003610500_bib4","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"2026041310003610500_bib5","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/nature13611","article-title":"Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function","volume":"514","author":"Viale","year":"2014","journal-title":"Nature"},{"key":"2026041310003610500_bib6","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.cell.2012.01.058","article-title":"Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism","volume":"149","author":"Ying","year":"2012","journal-title":"Cell"},{"key":"2026041310003610500_bib7","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1172\/JCI59227","article-title":"Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice","volume":"122","author":"Collins","year":"2012","journal-title":"J Clin Invest"},{"key":"2026041310003610500_bib8","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"2026041310003610500_bib9","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov"},{"key":"2026041310003610500_bib10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"2026041310003610500_bib11","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRASG12C inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N Engl J Med"},{"key":"2026041310003610500_bib12","doi-asserted-by":"crossref","first-page":"S751","DOI":"10.1016\/S1556-0864(21)01941-9","article-title":"99O_PR KRYSTAL-1: activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non\u2013small cell lung cancer (NSCLC) harboring KRASG12C mutation","volume":"16","author":"Riely","year":"2021","journal-title":"J Thoracic Oncol"},{"issue":"Suppl","key":"2026041310003610500_bib13","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0959-8049(20)31076-5","article-title":"KRYSTAL-1: activity and safety of adagrasib (MRTX849) in advanced\/ metastatic non\u2013small-cell lung cancer (NSCLC) harboring KRASG12C mutation","volume":"138","author":"J\u00e4nne","year":"2020","journal-title":"Eur J Cancer"},{"key":"2026041310003610500_bib14","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2303810","article-title":"Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation","volume":"389","author":"Sacher","year":"2023","journal-title":"N Engl J Med"},{"key":"2026041310003610500_bib15","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet"},{"key":"2026041310003610500_bib16","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1126\/science.adg9652","article-title":"Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS","volume":"381","author":"Schulze","year":"2023","journal-title":"Science"},{"key":"2026041310003610500_bib17","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/2159-8290.CD-22-0158","article-title":"Discovery, preclinical characterization, and early clinical activity of JDQ443, a structurally novel, potent, and selective covalent oral inhibitor of KRASG12C","volume":"12","author":"Weiss","year":"2022","journal-title":"Cancer Discov"},{"key":"2026041310003610500_bib18","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRASG12C inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N Engl J Med"},{"key":"2026041310003610500_bib19","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","article-title":"Diverse alterations associated with resistance to KRAS(G12C) inhibition","volume":"599","author":"Zhao","year":"2021","journal-title":"Nature"},{"key":"2026041310003610500_bib20","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","article-title":"Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation","volume":"11","author":"Tanaka","year":"2021","journal-title":"Cancer Discov"},{"key":"2026041310003610500_bib21","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1158\/1078-0432.CCR-19-3523","article-title":"Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition","volume":"26","author":"Ryan","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026041310003610500_bib22","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41586-019-1884-x","article-title":"Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition","volume":"577","author":"Xue","year":"2020","journal-title":"Nature"},{"key":"2026041310003610500_bib23","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ccell.2024.01.012","article-title":"Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer","volume":"42","author":"Tong","year":"2024","journal-title":"Cancer Cell"},{"key":"2026041310003610500_bib24","doi-asserted-by":"crossref","first-page":"e155523","DOI":"10.1172\/JCI155523","article-title":"Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition","volume":"132","author":"Tsai","year":"2022","journal-title":"J Clin Invest"},{"key":"2026041310003610500_bib25","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41698-022-00334-z","article-title":"Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors","volume":"6","author":"Lee","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"2026041310003610500_bib26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p.G12C\u2013mutated advanced pancreatic cancer","volume":"388","author":"Strickler","year":"2023","journal-title":"N Engl J Med"},{"key":"2026041310003610500_bib27","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in advanced solid tumors harboring a KRASG12C mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026041310003610500_bib28","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","article-title":"NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors","volume":"108","author":"Wang-Gillam","year":"2019","journal-title":"Eur J Cancer"},{"key":"2026041310003610500_bib29","doi-asserted-by":"crossref","first-page":"e2249720","DOI":"10.1001\/jamanetworkopen.2022.49720","article-title":"Effect of a MUC5AC antibody (NPC-1C) administered with second-line gemcitabine and nab-paclitaxel on the survival of patients with advanced pancreatic ductal adenocarcinoma: a randomized clinical trial","volume":"6","author":"Huffman","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026041310003610500_bib30","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","article-title":"Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor","volume":"28","author":"Hallin","year":"2022","journal-title":"Nat Med"},{"key":"2026041310003610500_bib31","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of MRTX1133, a noncovalent, potent, and selective KRASG12D inhibitor","volume":"65","author":"Wang","year":"2022","journal-title":"J Med Chem"},{"key":"2026041310003610500_bib32","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","article-title":"KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells","volume":"41","author":"Mahadevan","year":"2023","journal-title":"Cancer Cell"},{"key":"2026041310003610500_bib33","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1158\/2159-8290.CD-22-1066","article-title":"Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer","volume":"13","author":"Kemp","year":"2023","journal-title":"Cancer Discov"},{"key":"2026041310003610500_bib34","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1158\/0008-5472.CAN-23-1313","article-title":"Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma","volume":"83","author":"Gulay","year":"2023","journal-title":"Cancer Res"},{"key":"2026041310003610500_bib35","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cell.2014.06.004","article-title":"KRAS and YAP1 converge to regulate EMT and tumor survival","volume":"158","author":"Shao","year":"2014","journal-title":"Cell"},{"key":"2026041310003610500_bib36","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cell.2014.06.003","article-title":"Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer","volume":"158","author":"Kapoor","year":"2014","journal-title":"Cell"},{"key":"2026041310003610500_bib37","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccr.2009.03.022","article-title":"A gene expression signature associated with \u201cK-Ras addiction\u201d reveals regulators of EMT and tumor cell survival","volume":"15","author":"Singh","year":"2009","journal-title":"Cancer Cell"},{"key":"2026041310003610500_bib38","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nature21064","article-title":"Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer","volume":"542","author":"Genovese","year":"2017","journal-title":"Nature"},{"key":"2026041310003610500_bib39","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1158\/2159-8290.CD-19-0597","article-title":"Tumor microenvironment remodeling enables bypass of oncogenic KRAS dependency in pancreatic cancer","volume":"10","author":"Hou","year":"2020","journal-title":"Cancer Discov"},{"key":"2026041310003610500_bib40","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1101\/gad.348787.121","article-title":"USP21 deubiquitinase elevates macropinocytosis to enable oncogenic KRAS bypass in pancreatic cancer","volume":"35","author":"Hou","year":"2021","journal-title":"Genes Dev"},{"key":"2026041310003610500_bib41","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1158\/0008-5472.CAN-23-4070","article-title":"Transcriptomic profiling of plasma extracellular vesicles enables reliable annotation of the cancer-specific transcriptome and molecular subtype","volume":"84","author":"Bahrambeigi","year":"2024","journal-title":"Cancer Res"},{"key":"2026041310003610500_bib42","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nbt.3460","article-title":"High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines","volume":"34","author":"Yu","year":"2016","journal-title":"Nat Biotechnol"},{"key":"2026041310003610500_bib43","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s43018-019-0018-6","article-title":"Discovering the anticancer potential of non-oncology drugs by systematic viability profiling","volume":"1","author":"Corsello","year":"2020","journal-title":"Nat Cancer"},{"key":"2026041310003610500_bib44","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.1016\/j.cell.2021.11.017","article-title":"Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer","volume":"184","author":"Raghavan","year":"2021","journal-title":"Cell"},{"key":"2026041310003610500_bib45","doi-asserted-by":"crossref","first-page":"e18970","DOI":"10.7554\/eLife.18970","article-title":"KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer","volume":"6","author":"Krall","year":"2017","journal-title":"Elife"},{"key":"2026041310003610500_bib46","doi-asserted-by":"crossref","first-page":"15259","DOI":"10.1073\/pnas.1205508109","article-title":"Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110\u03b1 (PIK3CA)","volume":"109","author":"Burke","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026041310003610500_bib47","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ajhg.2012.10.021","article-title":"Germline PIK3CA and AKT1 mutations in cowden and cowden-like syndromes","volume":"92","author":"Orloff","year":"2013","journal-title":"Am J Hum Genet"},{"key":"2026041310003610500_bib48","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","article-title":"Integrated genomic characterization of pancreatic ductal adenocarcinoma","volume":"32","author":"Cancer Genome Atlas Research Network","year":"2017","journal-title":"Cancer Cell"},{"key":"2026041310003610500_bib49","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","article-title":"Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice","volume":"7","author":"Hingorani","year":"2005","journal-title":"Cancer Cell"},{"key":"2026041310003610500_bib50","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s41586-023-06130-4","article-title":"Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours","volume":"618","author":"Gavish","year":"2023","journal-title":"Nature"},{"key":"2026041310003610500_bib51","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/s41588-020-00726-6","article-title":"Pan-cancer single-cell RNA-seq identifies recurring programs of cellular heterogeneity","volume":"52","author":"Kinker","year":"2020","journal-title":"Nat Genet"},{"key":"2026041310003610500_bib52","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41588-022-01134-8","article-title":"Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment","volume":"54","author":"Hwang","year":"2022","journal-title":"Nat Genet"},{"key":"2026041310003610500_bib53","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/s41588-022-01141-9","article-title":"Cancer cell states recur across tumor types and form specific interactions with the tumor microenvironment","volume":"54","author":"Barkley","year":"2022","journal-title":"Nat Genet"},{"key":"2026041310003610500_bib54","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.cell.2015.05.047","article-title":"Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis","volume":"162","author":"Levine","year":"2015","journal-title":"Cell"},{"key":"2026041310003610500_bib55","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ccr.2011.08.014","article-title":"Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors","volume":"20","author":"De Raedt","year":"2011","journal-title":"Cancer Cell"},{"key":"2026041310003610500_bib56","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3390\/cancers12051327","article-title":"Patient-derived xenograft models of pancreatic cancer: overview and comparison with other types of models","volume":"12","author":"Garcia","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026041310003610500_bib57","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41588-019-0566-9","article-title":"Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution","volume":"52","author":"Chan-Seng-Yue","year":"2020","journal-title":"Nat Genet"},{"key":"2026041310003610500_bib58","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-17-2994","article-title":"Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial","volume":"24","author":"Aung","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026041310003610500_bib59","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1158\/1078-0432.CCR-19-3724","article-title":"GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer","volume":"26","author":"O\u2019Kane","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026041310003610500_bib60","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1053\/j.gastro.2023.05.038","article-title":"Transforming growth factor-\u03b2 blockade in pancreatic cancer enhances sensitivity to combination chemotherapy","volume":"165","author":"Qiang","year":"2023","journal-title":"Gastroenterology"},{"key":"2026041310003610500_bib61","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ccr.2012.04.024","article-title":"Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia","volume":"21","author":"Pylayeva-Gupta","year":"2012","journal-title":"Cancer Cell"},{"key":"2026041310003610500_bib62","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ccr.2012.04.025","article-title":"Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer","volume":"21","author":"Bayne","year":"2012","journal-title":"Cancer Cell"},{"key":"2026041310003610500_bib63","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","article-title":"EGFR blockade reverts resistance to KRASG12C inhibition in colorectal cancer","volume":"10","author":"Amodio","year":"2020","journal-title":"Cancer Discov"},{"key":"2026041310003610500_bib64","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat Med"},{"key":"2026041310003610500_bib65","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"key":"2026041310003610500_bib66","doi-asserted-by":"crossref","first-page":"1132319","DOI":"10.3389\/fonc.2023.1132319","article-title":"Targeting CLDN18.2 in cancers of the gastrointestinal tract: new drugs and new indications","volume":"13","author":"Chen","year":"2023","journal-title":"Front Oncol"},{"key":"2026041310003610500_bib67","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41586-023-06372-2","article-title":"Pharmacological targeting of netrin-1 inhibits EMT in cancer","volume":"620","author":"Lengrand","year":"2023","journal-title":"Nature"},{"key":"2026041310003610500_bib68","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41586-023-06367-z","article-title":"Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer","volume":"620","author":"Cassier","year":"2023","journal-title":"Nature"},{"key":"2026041310003610500_bib69","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ccell.2023.01.007","article-title":"CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance","volume":"41","author":"Nilsson","year":"2023","journal-title":"Cancer Cell"},{"key":"2026041310003610500_bib70","doi-asserted-by":"crossref","first-page":"eabm8780","DOI":"10.1126\/sciadv.abm8780","article-title":"Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers","volume":"8","author":"Mugarza","year":"2022","journal-title":"Sci Adv"},{"key":"2026041310003610500_bib71","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","article-title":"Pan-KRAS inhibitor disables oncogenic signalling and tumour growth","volume":"619","author":"Kim","year":"2023","journal-title":"Nature"},{"key":"2026041310003610500_bib72","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","article-title":"Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers","volume":"14","author":"Jiang","year":"2024","journal-title":"Cancer Discov"},{"key":"2026041310003610500_bib73","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s41586-024-07205-6","article-title":"Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy","volume":"629","author":"Holderfield","year":"2024","journal-title":"Nature"},{"key":"2026041310003610500_bib74","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41586-024-07379-z","article-title":"Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer","volume":"629","author":"Wasko","year":"2024","journal-title":"Nature"},{"key":"2026041310003610500_bib75","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026041310003610500_bib76","doi-asserted-by":"crossref","first-page":"e0176241","DOI":"10.1371\/journal.pone.0176241","article-title":"Collection of cell-free DNA for genomic analysis of solid tumors in a clinical laboratory setting","volume":"12","author":"Raymond","year":"2017","journal-title":"PLoS One"},{"key":"2026041310003610500_bib77","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/978-1-0716-0301-7_7","article-title":"Profiling cell type abundance and expression in bulk tissues with CIBERSORTx","volume":"2117","author":"Steen","year":"2020","journal-title":"Methods Mol Biol"},{"key":"2026041310003610500_bib78","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1158\/2159-8290.CD-21-0887","article-title":"Deconvolving clinically relevant cellular immune cross-talk from bulk gene expression using CODEFACS and LIRICS stratifies patients with melanoma to anti-PD-1 therapy","volume":"12","author":"Wang","year":"2022","journal-title":"Cancer Discov"},{"key":"2026041310003610500_bib79","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"2026041310003610500_bib80","doi-asserted-by":"crossref","first-page":"751","DOI":"10.5858\/arpa.2016-0527-OA","article-title":"Validation of OncoPanel: a targeted next-generation sequencing assay for the detection of somatic variants in cancer","volume":"141","author":"Garcia","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"2026041310003610500_bib81","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.immuni.2018.06.006","article-title":"Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy","volume":"49","author":"Li","year":"2018","journal-title":"Immunity"},{"key":"2026041310003610500_bib82","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"2026041310003610500_bib83","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat Methods"},{"key":"2026041310003610500_bib84","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.celrep.2016.05.063","article-title":"In vivo functional platform targeting patient-derived xenografts identifies WDR5-myc association as a critical determinant of pancreatic cancer","volume":"16","author":"Carugo","year":"2016","journal-title":"Cell Rep"},{"key":"2026041310003610500_bib85","doi-asserted-by":"crossref","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep"},{"key":"2026041310003610500_bib86","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1158\/0008-5472.CAN-22-3050","article-title":"Spatially resolved single-cell assessment of pancreatic cancer expression subtypes reveals co-expressor phenotypes and extensive intratumoral heterogeneity","volume":"83","author":"Williams","year":"2023","journal-title":"Cancer Res"},{"key":"2026041310003610500_bib87","first-page":"275","article-title":"False discovery rates: a new deal","volume":"18","author":"Stephens","year":"2017","journal-title":"Biostatistics"},{"key":"2026041310003610500_bib88","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/ng.3398","article-title":"Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma","volume":"47","author":"Moffitt","year":"2015","journal-title":"Nat Genet"},{"key":"2026041310003610500_bib89","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1158\/0008-5472.CAN-22-1742","article-title":"Systematic comparison of pancreatic ductal adenocarcinoma models identifies a conserved highly plastic basal cell state","volume":"82","author":"Pitter","year":"2022","journal-title":"Cancer Res"},{"key":"2026041310003610500_bib90","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nm.2344","article-title":"Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy","volume":"17","author":"Collisson","year":"2011","journal-title":"Nat Med"},{"key":"2026041310003610500_bib91","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/doi\/10.1158\/2159-8290.CD-24-0177\/3472224\/cd-24-0177.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/doi\/10.1158\/2159-8290.CD-24-0177\/3503232\/cd-24-0177.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/14\/11\/2135\/3509880\/cd-24-0177.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/14\/11\/2135\/3509880\/cd-24-0177.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:00:53Z","timestamp":1776088853000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/14\/11\/2135\/749207\/Mechanisms-of-Resistance-to-Oncogenic-KRAS"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,5]]},"references-count":91,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,7,5]]},"published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-24-0177","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2159-8290.27435426","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.27435438","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.27435435","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.27435447","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.27435417","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.27435429","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.27435441","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32699694","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.27435444","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.27435411","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32699691","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.27435420","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32699718","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32699709","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32699721","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32699700","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32699712","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32699724","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32699703","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32699715","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.c.7520412","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,5]]}}}